The FDA has approved Inveltys, a twice-daily ocular corticosteroid, for the treatment of postoperative inflammation and pain after ocular surgery, according to a Kala Pharmaceuticals press release.
Inveltys (loteprednol etabonate ophthalmic suspension 1%) is the first twice-daily ocular steroid for the treatment of inflammation and pain after ocular surgery to be approved by the FDA.
“Prior to the launch of Inveltys, all available post-surgical corticosteroids were approved with four-times-a-day dosing. This more frequent dosing requirement can lead to issues for both doctors and
Uncategorized